Shares of Unity Biotechnology, Inc. UBX plunged 53% after the company announced disappointing results from Part A of the phase II ENVISION study of UBX1325 in patients with wet age-related macular ...
UNITY Biotechnology, Inc. reported its financial results for the first quarter of 2025, highlighting the 24-week and partial 36-week topline data from its Phase 2b ASPIRE study in diabetic macular ...
UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population UBX1325 generally outperformed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results